USA - NASDAQ:CNSP - US18978H5081 - Common Stock
Overall CNSP gets a fundamental rating of 2 out of 10. We evaluated CNSP against 192 industry peers in the Pharmaceuticals industry. CNSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CNSP has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -106.55% | ||
| ROE | -117.78% | ||
| ROIC | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.4 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.22 | ||
| Quick Ratio | 10.22 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
7.51
-0.09 (-1.18%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.33 | ||
| P/tB | 0.33 | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -106.55% | ||
| ROE | -117.78% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.22 | ||
| Quick Ratio | 10.22 | ||
| Altman-Z | -9.4 | 
ChartMill assigns a fundamental rating of 2 / 10 to CNSP.
ChartMill assigns a valuation rating of 1 / 10 to CNS PHARMACEUTICALS INC (CNSP). This can be considered as Overvalued.
CNS PHARMACEUTICALS INC (CNSP) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of CNS PHARMACEUTICALS INC (CNSP) is expected to grow by 92.81% in the next year.